

SIERRA LEONE Support for Measles Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Sierra Leone			
2. Grant number: 17-SLE-09a-X			
3. Date of Decision Letter: 13 June 2017			
4. Date of the Partnership Framework Agreement: 10 March 2013			
5. Programme title: New vaccine support (NVS), Measles Second Dose			
6. Vaccine type: Measles			
7. Requested product presentation and formulation of vaccine: 10 doses/vial, lyophilised			
8. Programme duration¹: 2015 – 2017			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2015 - 2016	2017	Total ²
Programme Budget (US\$)	US\$130,500 ³	US\$150,000	US\$280,500
10. Vaccine introduction grant (in US\$): Not applicable			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2015 - 2016	2017	
Number of vaccines doses		507,200	
Annual Amounts (US\$)	US\$130,500 ⁵	US\$150,000	

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

For information and reference, the related Injection Safety Devices to be purchased under Gavi funds for 2017 shall be included in a separate Decision Letter (Grant Number 17-SLE-32a-X):

New Vaccine Support (NVS), Measles, 10 dose(s) per vial, LYOPHILISED,SD Routine - Strat 1	2017
Number of AD syringes	458,100
Number of re-constitution syringes	55,800
Number of safety boxes	5,675
Annual Amounts for Injection Safety Devices for Vaccine (US\$)	25,500

12. Procurement agency: UNICEF

13. Self-procurement: Not applicable

14. Co-financing obligations: Not applicable


15. Operational support for campaigns: The country shall submit the external audit report for 2015.

16. Additional reporting requirements: Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

13 June 2017

SIERRA LEONE Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Sierra Leone			
2. Grant number: 17-SLE-04c-X			
3. Date of Decision Letter: 13 June 2017			
4. Date of the Partnership Framework Agreement: 10 March 2013			
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID			
8. Programme duration⁶: 2007 - 2017			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2007 - 2016	2017	Total ⁷
Programme Budget (US\$)	US\$16,746,949 ⁸	US\$357,500	US\$17,104,449
10. Vaccine introduction grant (in US\$): Not applicable			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁹			
Type of supplies to be purchased with Gavi funds in each year	2007 - 2016	2017	
Number of Pentavalent vaccines doses		298,500	
Annual Amounts (US\$)	US\$16,746,949 ¹⁰	US\$357,500	

⁶ This is the entire duration of the Programme.

⁷ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁸ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁹ This is the amount that Gavi has approved.

¹⁰ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

For information and reference, the related Injection Safety Devices to be purchased under Gavi funds for 2017 shall be included in a separate Decision Letter (Grant Number 17-SLE-32a-X):

New Vaccine Support (NVS), DTP-HepB-Hib, 10 dose(s) per vial, LIQUID, Routine	2017
Number of AD syringes	362,100
Number of re-constitution syringes	
Number of safety boxes	4,000
Annual Amounts for Injection Safety Devices for Vaccine (US\$)	18,500

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. Self-procurement: Not applicable

14. Co-financing obligations: Reference code: 17-SLE-04c-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017
Number of vaccine doses	60,000
Number of AD syringes	
Number of re-constitution syringes	
Number of safety boxes	
Value of vaccine doses (US\$)	US\$70,239
Total co-financing payments (US\$) (including freight)	US\$72,000

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

13 June 2017

SIERRA LEONE Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Sierra Leone			
2. Grant number: 17-SLE-12c-X			
3. Date of Decision Letter: 13 June 2017			
4. Date of the Partnership Framework Agreement: 10 March 2013			
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID			
8. Programme duration¹: 2010 - 2017			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2010 - 2016	2017	Total ²
Programme Budget (US\$)	US\$21,634,527 ³	US\$2,336,000	US\$23,970,527
10. Vaccine introduction grant (in US\$): Not applicable.			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2010 -2016	2017	
Number of Pneumococcal vaccines doses		622,100	
Annual Amounts (US\$)	US\$21,634,527 ⁵	US\$2,336,000	

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

For information and reference, the related Injection Safety Devices to be purchased under Gavi funds for 2017 shall be included in a separate Decision Letter (Grant Number 17-SLE-32a-X):

New Vaccine Support (NVS), Pneumococcal (PCV13), 1 dose(s) per vial LIQUID,Routine	2017
Number of AD syringes	702,500
Number of re-constitution syringes	
Number of safety boxes	7,750
Annual Amounts for Injection Safety Devices for Vaccine (US\$)	35,500

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. Self-procurement: Not applicable

14. Co-financing obligations: Reference code: 17-SLE-12c-X-C
According to the co-financing policy, the Country falls within the group Initial self-financing.
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017
Number of vaccine doses	38,300
Number of AD syringes	
Number of re-constitution syringes	
Number of safety boxes	
Value of vaccine doses (US\$)	US\$126,066
Total co-financing payments (US\$) (including freight)	US\$132,500

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

13 June 2017

SIERRA LEONE Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Sierra Leone			
2. Grant number: 17-SLE-13b-X			
3. Date of Decision Letter: 13 June 2017			
4. Date of the Partnership Framework Agreement: 10 March 2013			
5. Programme title: New Vaccine Support (NVS), Rotavirus Routine			
6. Vaccine type: Rotavirus			
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule			
8. Programme duration¹¹: 2014 - 2017			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2014-2016	2017	Total ¹²
Programme Budget (US\$)	US\$3,093,225 ¹³	US\$992,500	US\$4,085,725
10. Vaccine introduction grant (in US\$): Not applicable			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ¹⁴			
Type of supplies to be purchased with Gavi funds in each year	2014-2016	2017	
Number of Rotavirus vaccines doses		441,000	
Annual Amounts (US\$)	US\$3,093,225 ¹⁵	US\$992,500	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			

¹¹ This is the entire duration of the Programme.

¹² This is the total amount endorsed by Gavi for the entire duration of the Programme.

¹³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

¹⁴ This is the amount that Gavi has approved.

¹⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

14. Co-financing obligations: Reference code: 17-SLE-13b-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017
Number of vaccine doses	43,500
Number of AD syringes	
Number of re-constitution syringes	
Number of safety boxes	
Value of vaccine doses (US\$)	US\$94,390
Total co-financing payments (US\$) (including freight)	US\$97,000

15. Operational support for campaigns: Not applicable


16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

13 June 2017

**SIERRA LEONE
Support for Yellow Fever Vaccine**

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Sierra Leone			
2. Grant number: 17-SLE-06b-X			
3. Date of Decision Letter: 13 June 2017			
4. Date of the Partnership Framework Agreement: 10 March 2013			
5. Programme title: NVS, Yellow Fever Routine			
6. Vaccine type: Yellow Fever			
7. Requested product presentation and formulation of vaccine: Yellow Fever, 10 dose(s) per vial, LYOPHILISED			
8. Programme duration¹: 2003 – 2017			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2003 - 2016	2017	Total ²
Programme Budget (US\$)	US\$2,533,060 ³	US\$279,500	US\$2,812,560
10. Vaccine introduction grant (in US\$): Not applicable			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable): ⁴			
Type of supplies to be purchased with Gavi funds in each year	2003 - 2016	2017	
Number of Yellow Fever vaccines doses		243,800	
Annual Amounts (US\$)	US\$2,533,060 ⁵	US\$279,500	

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

For information and reference, the related Injection Safety Devices to be purchased under Gavi funds for 2017 shall be included in a separate Decision Letter (Grant Number 17-SLE-32a-X):

New Vaccine Support (NVS), Yellow Fever, 10 dose(s) per vial, LYOPHILISED, Routine	2017
Number of AD syringes	303,800
Number of re-constitution syringes	32,500
Number of safety boxes	3,700
Annual Amounts for Injection Safety Devices for Vaccine (US\$)	17,000

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. Self-procurement: Not applicable

14. Co-financing obligations: Reference code: 17-SLE-06b-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017
Number of vaccine doses	51,600
Number of AD syringes	
Number of re-constitution syringes	
Number of safety boxes	
Value of vaccine doses (US\$)	US\$56,718
Total co-financing payments (US\$) (including freight)	US\$59,500

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Financial clarifications: Not applicable	
<p>17. Other conditions: There is currently a global shortage in the supply of yellow fever vaccines. The number of doses and presentation are subject to availability. Gavi will inform the Government as soon as possible of any changes in doses and/or presentation from what has been communicated to the Country.</p>	

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

13 June 2017